Closely held Kaleo said Adamis’s proposed generic version of its auto-injector antidote to opioid overdoses infringes three patents for Evzio.
- Kaleo is seeking a court order blocking copies until the patents have expired, and to collect cash compensation if copies are made before then, according to complaint filed Thursday in federal court in Wilmington, Delaware
- Patents expire in February and May 2031 and in January 2034, according to supplemental filing
- NOTE: Opioid Antidote Price Hikes Cost Taxpayer Millions, Senators Say
- NOTE: FDA Gives Pharma a Boost to Develop OTC Opioid Overdose Antidote
- CASE: Kaleo Inc. v. Adamis Pharmaceuticals Corp., 19-cv-917 ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.